DK1206474T3 - Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer - Google Patents
Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorerInfo
- Publication number
- DK1206474T3 DK1206474T3 DK00955867T DK00955867T DK1206474T3 DK 1206474 T3 DK1206474 T3 DK 1206474T3 DK 00955867 T DK00955867 T DK 00955867T DK 00955867 T DK00955867 T DK 00955867T DK 1206474 T3 DK1206474 T3 DK 1206474T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds useful
- cox
- inhibitors
- sulfonylphenylpyrazole
- sulfonylphenylpyrazole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38495499A | 1999-08-27 | 1999-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1206474T3 true DK1206474T3 (da) | 2004-10-04 |
Family
ID=23519433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00955867T DK1206474T3 (da) | 1999-08-27 | 2000-08-24 | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1206474B1 (fr) |
JP (1) | JP2003508401A (fr) |
AT (1) | ATE267830T1 (fr) |
CA (1) | CA2379421A1 (fr) |
DE (1) | DE60011100T2 (fr) |
DK (1) | DK1206474T3 (fr) |
ES (1) | ES2222919T3 (fr) |
MX (1) | MXPA02002111A (fr) |
PT (1) | PT1206474E (fr) |
WO (1) | WO2001016138A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2166710B1 (es) * | 2000-04-25 | 2004-10-16 | J. URIACH & CIA, S.A. | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
PT1397364E (pt) * | 2001-05-24 | 2007-10-22 | Lilly Co Eli | Novos derivados de pirrole como agentes farmacêuticos |
KR100478467B1 (ko) * | 2002-06-24 | 2005-03-23 | 씨제이 주식회사 | 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물 |
EP1572113B1 (fr) | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Compose modulateur de recepteur de calcium et utilisation associee |
EP1542680B1 (fr) | 2002-09-09 | 2007-03-07 | Amgen Inc. | Derivés de 1, 2-dihydro-pyrazol-3-one et 3-alcoxy-1h-pyrazole substitués 1, 4, 5-pour l'utilisation comme agents reduisant le tnf-alpha et l'interleukine dans le traitement des inflammations |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
AU2003291642A1 (en) * | 2002-11-22 | 2004-06-18 | Eli Lilly And Company | Pyrazoloazepine compounds as pharmaceutical agents |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
EP2024349B1 (fr) | 2006-05-31 | 2017-08-02 | AbbVie Inc. | Composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés |
MX2009010363A (es) | 2007-03-28 | 2009-12-04 | Abbott Lab | Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide. |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2010033543A2 (fr) | 2008-09-16 | 2010-03-25 | Abbott Laboratories | Composés inédits utilisables en tant que ligands des récepteurs cannabinoïdes |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
WO2010147898A2 (fr) * | 2009-06-15 | 2010-12-23 | Rigel Pharmaceuticals, Inc. | Inhibiteurs à petite molécule de la tyrosine kinase de la rate (syk) |
AR080055A1 (es) * | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
CN104039785A (zh) | 2011-10-06 | 2014-09-10 | 拜耳知识产权有限责任公司 | 作为杀真菌剂的杂环基吡(嘧)啶基吡唑 |
EP2852586A1 (fr) | 2012-03-16 | 2015-04-01 | Axikin Pharmaceuticals, Inc. | Inhibiteurs de 3,5-diaminopyrazole kinase |
HUE031980T2 (en) | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
CN103232394B (zh) * | 2013-05-14 | 2014-09-24 | 浙江医药高等专科学校 | 含吡唑类化合物、其制备方法和用途 |
MX2016003292A (es) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos. |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
US10927117B2 (en) | 2016-08-16 | 2021-02-23 | Beigene Switzerland Gmbh | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
DK3500299T3 (da) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
KR102596307B1 (ko) | 2017-04-27 | 2023-10-30 | 바이엘 애니멀 헬스 게엠베하 | 새로운 비시클릭 피라졸 유도체 |
CA3066518A1 (fr) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapie pour carcinome hepatocellulaire |
US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824834A (en) * | 1986-10-31 | 1989-04-25 | Otsuka Pharmaceutical Company, Limited | Pyrazolotriazine compounds |
JP2665564B2 (ja) * | 1989-08-25 | 1997-10-22 | 株式会社大塚製薬工場 | 細胞防護剤 |
JP2691317B2 (ja) * | 1989-08-25 | 1997-12-17 | 株式会社大塚製薬工場 | 4―ヒドロキシ―8―(3―低級アルコキシ―4―フェニルスルフィニルフェニル)ピラゾロ〔1,5―a〕―1,3,5―トリアジン光学活性体の塩類及びその製造方法 |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
JPH07118272A (ja) * | 1993-10-19 | 1995-05-09 | Otsuka Pharmaceut Co Ltd | 4−ヒドロキシピラゾロトリアジン誘導体およびその光学活性体の製造方法 |
US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
WO1996014302A1 (fr) * | 1994-11-08 | 1996-05-17 | Eisai Co., Ltd. | Derives pyrazole presentant des effets anti-inflammatoires et analgesiques |
GB9422667D0 (en) * | 1994-11-10 | 1995-01-04 | Zeneca Ltd | Herbicides |
GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
JPH10310578A (ja) * | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3−フェニルピラゾール化合物 |
-
2000
- 2000-08-24 JP JP2001519704A patent/JP2003508401A/ja not_active Withdrawn
- 2000-08-24 ES ES00955867T patent/ES2222919T3/es not_active Expired - Lifetime
- 2000-08-24 PT PT00955867T patent/PT1206474E/pt unknown
- 2000-08-24 EP EP00955867A patent/EP1206474B1/fr not_active Expired - Lifetime
- 2000-08-24 AT AT00955867T patent/ATE267830T1/de not_active IP Right Cessation
- 2000-08-24 DK DK00955867T patent/DK1206474T3/da active
- 2000-08-24 CA CA002379421A patent/CA2379421A1/fr not_active Abandoned
- 2000-08-24 MX MXPA02002111A patent/MXPA02002111A/es not_active Application Discontinuation
- 2000-08-24 DE DE60011100T patent/DE60011100T2/de not_active Expired - Fee Related
- 2000-08-24 WO PCT/US2000/023214 patent/WO2001016138A1/fr active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
PT1206474E (pt) | 2004-10-29 |
JP2003508401A (ja) | 2003-03-04 |
DE60011100D1 (de) | 2004-07-01 |
CA2379421A1 (fr) | 2001-03-08 |
DE60011100T2 (de) | 2005-06-16 |
WO2001016138A1 (fr) | 2001-03-08 |
ES2222919T3 (es) | 2005-02-16 |
ATE267830T1 (de) | 2004-06-15 |
MXPA02002111A (es) | 2002-10-31 |
EP1206474A1 (fr) | 2002-05-22 |
EP1206474B1 (fr) | 2004-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
NO20030374D0 (no) | Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter | |
NO20061122L (no) | 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer | |
NO20070866L (no) | Antivirale forbindelser. | |
WO2003073999A3 (fr) | Composes de modulation de pin1 et procedes d'utilisation correspondant | |
WO2003074550A3 (fr) | Composes de modulation de pin1 et procedes d'utilisation correspondant | |
ATE358669T1 (de) | Pyrazolderivate zur behandlung von hiv | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
CY1106357T1 (el) | Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
NO20014986L (no) | 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer | |
NO955256L (no) | Fenylheterosykluser som syklooksygenase-2-inhibitorer | |
SE0301700D0 (sv) | Novel compounds | |
NO981628D0 (no) | (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
NO20052794L (no) | Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse | |
ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
SE9901077D0 (sv) | Novel use | |
WO2005007123A3 (fr) | Composes modulateurs de pin-1 et methodes d'utilisation associees | |
SE0302304D0 (sv) | Novel compounds | |
ES2147973T3 (es) | Estirenos alquilatados como profarmacos de inhibidores de cox-2. | |
DE60329326D1 (de) | Tace inhibitoren | |
NO983511D0 (no) | Difenylstilbener som pro-legemidler for COX-2-inhibitorer | |
ATE223376T1 (de) | Bisarylcyclobutenderivate als cyclooxygenasehemmer |